Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXERRT: Regadenoson MPI after Inadequate Exercise
NCT01618669Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2012
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of regadenoson in coronary artery disease (CAD), sponsored by Astellas Pharma. Started Jun 2012; status: completed.
02
Drugs
regadenoson
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01618669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01618669.